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Tubulin is essential to eukaryotic cells and is targeted by several antineoplastics, herbicides, and antimi-
crobials. We demonstrate that Acanthamoeba spp. are resistant to five antimicrotubule compounds, unlike any
other eukaryote studied so far. Resistance correlates with critical amino acid differences within the inhibitor
binding sites of the tubulin heterodimers.
Tubulin is an essential structural element of the cytoskeleton
of eukaryotic cells, where it plays a central role in chromo-
somal segregation, organelle movement, and cellular motility
(7, 21). Tubulin has been exploited as a target for antineoplas-
tics (8, 25), herbicides (18), and antihelminthic (9, 23), anti-
fungal (14), and antiprotozoal (27, 28, 29) compounds. In ad-
dition, colchicine has been used for the treatment of gout in
humans (2). Despite the highly conserved nature of -tubulin
and -tubulin across the phyla, organisms present diverse de-
grees of susceptibility and resistance to the different groups of
antimicrotubule agents. The success of benzimidazoles and
dinitroanilines is due to their selectivity for helminths and
plants, respectively, and their low toxicity in mammals (6, 23).
However, even within these broad classifications of organisms
there are many important differences. Some protozoans, in-
cluding apicomplexans, are susceptible to dinitroanilines (e.g.,
Toxoplasma gondii, with a 50% inhibitory concentration [IC50]
of 0.3 M [19]), while others, such as Trypanosoma cruzi (IC50
of 17.6 M), are resistant (26, 27). Similarly, there is consid-
erable variation in susceptibility of protozoans to paclitaxel, as
exemplified by Leishmania spp. (IC50 of 35 nM) (10) and T.
gondii (IC50 of 1 M) (4). A few protozoa, such as Giardia
lamblia, are susceptible to benzimidazoles, a class of drug nor-
mally used to treat helminth infections (14). Studies have dem-
onstrated that amino acid differences that influence tertiary
structure or alter inhibitor-docking regions are responsible for
determining resistance to antitubulins. For example, site-di-
rected mutagenesis in the oryzalin-docking site on -tubulin in
T. gondii and Eleusine indica has been successful in altering the
phenotype to oryzalin resistant (6, 19, 24).
Using the previously described alamar blue assay (17), we
demonstrated that the two species of Acanthamoeba most com-
monly reported as causing Acanthamoeba keratitis in humans
(15, 16, 20), A. castellanii and A. polyphaga, are resistant to five
classes of tubulin inhibitor represented by oryzalin, paclitaxel,
vinblastine, albendazole, and colchicine (Table 1).
To explore the potential basis for these observations, both -
and -tubulin genes were cloned and sequenced from A. cas-
tellanii (neff strain) and A. polyphaga (strain 1501/18) (GenBank
accession numbers DQ099493, DQ099491, DQ0994494, and
DQ099492). The sequence identity on the amino acid level
between the two species is 67% for -tubulin and 99% for
-tubulin (see the table in the supplemental material). By
using previously solved tubulin structures and their known
inhibitor binding sites, it has been possible to model the tubu-
lins from both species of Acanthamoeba and predicted inhibi-
tor interactions.
Structure-based mutagenesis studies of T. gondii -tubulin
have suggested that oryzalin binds in a pocket formed by 13
residues (19), of which 8 are identical in the Acanthamoeba
family. Two of the residues which display sequence variation
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TABLE 1. Relative IC50s of Acanthamoeba species and rabbit
corneal cells (RCE) to antitubulin compoundsa
Compound
IC50
A. polyphaga A. castellanii RCE
Oryzalin 100 M 100 M 500 M
Paclitaxel 10 M 10 M 0.04–0.08 M
Vinblastine 0.68–1.375 M 0.68–1.375 M 17 nM
Albendazole 47 M 47 M 0.7–1.469 M
Colchicine 2.5–5 mM 2.5 mM 2.4 M
a Both A. castellanii and A. polyphaga were susceptible to chlorhexidine (IC50s
were 1.5625 to 3.125 M and 3.125 to 6.25 M, respectively).
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(Ile42 and Asp47) lie within the N loop, implicated in inhibitor
binding (Fig. 1; also see the figure in the supplemental mate-
rial), which is also shorter than other -tubulin homologues by
2 residues, contributing to the loss of potency. Val4Ile (i.e.,
valine at position 4 in the oryzalin-sensitive T. gondii -tubulin
is replaced by an isoleucine at position 4 in Acanthamoeba
-tubulin), Phe24Tyr, and Cys65Ala replacements are pre-
dicted to have a more subtle effect on the inhibitor pocket
shape.
Paclitaxel binds to the -tubulin subunit (13), and the struc-
ture of the mammalian (Bos taurus) -tubulin/paclitaxel com-
plex reveals that 22 residues form the inhibitor binding pocket;
7 of these residues show sequence variation relative to the
Acanthamoeba proteins (Ala231Gln, Phe270Tyr, Ser275Ala,
Arg276Pro, Gln279Thr, Arg359Ala, and Leu361Gln replace-
ments). Significantly, Ala231, which is in the heart of the in-
hibitor binding pocket, is replaced by Gln, producing a severe
steric clash to the inhibitor (Fig. 1). An additional steric clash
may be formed by the replacement of Leu361 with Gln, with
Phe270Tyr and Arg276Pro (Table 2) changing the packing
interactions to the inhibitor. The remaining changes are sol-
vent exposed and predicted to make little difference to inhib-
itor binding.
Vinblastine binds at the interface between - and -tubulin
subunits (5). Of the 23 residues that have been implicated in
inhibitor binding, 4 show sequence variation relative to mam-
malian tubulin within A. castellanii and A. polyphaga proteins:
Val353Cys and Asn329His (for A. castellanii) or Asn329Ser
(for A. polyphaga) in -tubulin and Thr219Asn and Thr221Asn
in -tubulin (22) (Table 2). The Thr221Asn replacement in
-tubulin may result in a steric clash with the inhibitor. In
addition, Asn329 in -tubulin makes close interactions with the
inhibitor and its replacement by His (in A. castellanii) may
result in a steric clash whereas its replacement by Ser (in A.
polyphaga) results in a loss of the packing interactions. For
A. castellanii, there are three additional changes not found in
A. polyphaga, which can affect inhibitor binding (Ile355Val,
Phe351Pro, and Pro325Thr replacements) (Fig. 1).
Of the 13 residues which form the putative albendazole
inhibitor binding site (12), 4 show sequence variation in the
Acanthamoeba family (Table 2). Albendazole resistance is con-
FIG. 1. Structural representation of the predicted Acanthamoeba tu-
bulin inhibitor binding pocket for the five tubulin inhibitors oryzalin,
paclitaxel, vinblastine, albendazole, and colchicine. For all panels, - and
-tubulin are colored magenta and blue, respectively, and each inhibitor
is colored gray. The residues that bind the inhibitor are represented in a
stick format, with those that are divergent within the Acanthamoeba fam-
ily colored green and labeled. In panel a, the N-loop of -tubulin, which
plays a role in forming close interactions with oryzalin, is shown in yellow.
All structures are based on the B. taurus tubulin structure and were
produced using the graphics program PyMOL (3).
TABLE 2. Key amino acid residue changes in inhibitor binding sites between susceptible organisms and resistant Acanthamoeba spp.
Compound Organism Phenotype
Residue in:
-Tubulin -Tubulin
Oryzalin E. indica Susceptible Ile42 Asp47 Val4 Phe24 Cys65
Acanthamoeba Resistant Ile4 Tyr24 Ala65
Paclitaxel B. taurus Susceptible Ala231 Phe270 Ser275 Arg276 Gln279 Arg359 Leu361
Acanthamoeba Resistant Gln231 Tyr270 Ala275 Pro276 Thr279 Ala359 Gln361
Vinblastine Homo sapiens Susceptible Val353 Asn329 Ile355 Pro325 Phe351 Thr219 Thr221
Acanthamoeba Resistant Cys353 His329 (c)a Val355 (c) Thr325 (c) Pro351 (c) Asn219 Asn221
Ser329 (p)
Albendazole A. nidulans Susceptible Ala165 Phe167 Glu198 Phe200
Acanthamoeba Resistant Cys165 Ser167 Gln198 Met200
Colchicine Homo sapiens Susceptible Val313 Ala314 Ile316
Acanthamoeba Resistant Ala313 Ser314 Val316
a c, A. castellanii; p, A. polyphaga.
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ferred when Phe167 and Phe200 are replaced by serine and
methionine, respectively. The latter replacement is also
present in Leishmania spp. (1, 11). The replacement of Ala165
in susceptible helminth tubulin with a cysteine in Giardia duo-
denalis and Encephalitozoon cuniculi has been shown to confer
resistance to several members of the benzimidazole family
when mutated to a larger residue (11).
Analysis of Acanthamoeba -tubulin has shown that the key
mammalian colchicine-sensitive residues Val313, Ala314,
Ala315, and Ile316 (Table 2) are replaced in Acanthamoeba by
Ala, Ser, Ala, and Val, respectively, as they are present in
colchicine-resistant Leishmania spp. (28, 29). In addition, there
is a significant change in the environment of the hydrophobic
colchicine binding pocket due to the replacement of 4 Ala
residues with bulkier Ser residues, which increases the percent-
age of hydrophilic residues from approximately 30% to 55%.
To verify that the sequence divergence of Acanthamoeba
tubulin is responsible for the resistance of Acanthamoeba tu-
bulin to all five compounds tested, future work should involve
biochemical and structural analyses of Acanthamoeba tubulins.
An important consideration is that resistance to these tubulin
inhibitors may not be based upon changes in the inhibitor
binding site alone; other factors, such as drug metabolism,
compartmentalization, or efflux, must also be potential factors.
The work presented here demonstrates that the Acanthamoeba
- and -tubulins are both unusually divergent from tubulins of
other organisms and offers plausible evidence for the unusual
behavior of Acanthamoeba species in the presence of tubulin
polymerizing and depolymerizing inhibitors.
The William Ross Foundation and the University of Strathclyde
Research and Development Fund funded this work.
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